Led · Seed · May 2026

Sedivention is developing a minimally invasive outpatient therapy that uses a specially designed balloon catheter to deliver targeted cryoablation to interrupt hunger-related signals in the vagus nerve. A functional prototype has been developed and tested, and the company aims to generate initial clinical data via a first-in-human study. With the €2.9M seed round, Sedivention plans to advance product development and prepare for regulatory and market-entry steps. The therapy is intended as a one-time procedure without implants or ongoing medication and aims to offer a scalable alternative to bariatric surgery and chronic drug therapies. In the long term, Sedivention seeks to replace highly invasive surgical procedures with outpatient interventional treatments to improve access to effective obesity care.

Participated · Series B · Apr 2026

SOLAR MATERIALS has developed a patented process to recover high-quality, sort-pure materials — including glass, aluminum, copper, silver and silicon — from end-of-life crystalline silicon solar modules, which comprise more than 95% of the global installed base. The technology has been industrially validated and the company positions modules as a resource rather than waste, addressing rising volumes of retired panels in Europe. SOLAR MATERIALS is scaling its recycling technology across larger industrial sites and is working to extend the process to additional module technologies. The company has secured up to €20 million in a Series B to accelerate European scale-up and site buildout, and has formed a strategic partnership with NOVA by Saint-Gobain to feed recycled glass into float-glass production. No specific revenue, user or other operating metrics were disclosed in the article.

Participated · Series A · Mar 2026

Raydiax is a 2022 spin-off from the STIMULATE research campus at Otto von Guericke University Magdeburg that is building TACT, a therapy assistance CT scanner designed for use directly in operating rooms. The system offers real-time, focused CT imaging that supports planning, execution, and monitoring of interventional oncology procedures while aiming to cut radiation exposure, shorten procedure times, and enable new techniques such as robot-assisted surgery through a larger gantry opening. Having completed a pre-clinical prototype during its seed phase, the company is now preparing first-in-human studies and moving the device toward production readiness and regulatory approval. Raydiax will also scale its sales, manufacturing, and quality functions in advance of initial commercial installations. Management believes the technology fills a critical workflow gap in interventional radiology and could establish a new device category for minimally invasive cancer treatment. The firm is headquartered in Magdeburg’s Science Harbor and is led by CEO and co-founder Dr. Thomas Hoffmann. Current financial backing totals €7.5 million in Series A1 capital, supplemented by earlier seed funding (undisclosed).

Participated · Seed · Mar 2026

Litherm Technologies GmbH has created a completely electricity-based calcination technology that eliminates combustion and the associated fossil-fuel CO₂ emissions in lime and cement production. The system employs a highly efficient fluidized-bed design, capturing the process-generated CO₂ in concentrated form for CCU or CCS pathways without additional energy input. Litherm has already built a pilot plant at a Fels-Werke GmbH site in Sachsen-Anhalt and plans to move toward commercial demonstration units. The newly raised capital will fund further industrialization, engineering, construction, and commissioning of these first commercial demo plants. Industrial players such as Graymont, SigmaRoc (via SkreenHouse Ventures), and Kalkfabrik Netstal AG are involved to accelerate scale-up and market entry. Climate-focused investors like Breakthrough Energy Foundation complement the industrial backers. The seed financing of more than €6.5 million provides the resources for Litherm to advance its technology to full industrial readiness.

Participated · Seed · Oct 2025

Founded in 2024 in Leipzig, aevoloop has created a patented chemistry that introduces selectively cleavable bonds into polyethylene and polypropylene chains, allowing the materials to be broken back down into virgin-grade monomers at end-of-life. The resulting plastics match the mechanical properties and processing profiles of conventional polyolefins, so they can run on existing extruders and injection-moulding lines without cost penalties. Because the polymers are also biodegradable, the platform targets both macro- and microplastic pollution. Initial application areas include packaging, films, injection-moulded parts and textiles, with the company aiming to scale toward industrial production and broaden use cases across the plastic value chain. aevoloop is collaborating with the Leibniz Institute of Polymer Research, Leipzig University and the Center for the Transformation of Chemistry under the “Saxy Plastics” project to accelerate R&D and commercialization. The startup just secured about €8 million in fresh capital—€3.25 million in seed equity plus nearly €5 million in public co-funding—providing runway for pilot production and market launch activities.